Free Webex Call
The Global Lateral Flow Assay Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of infectious diseases such as TB, Hepatitis, and Influenza STI, along with the growing demand for point-of-care testing. Similarly, the growing adoption of new technology like lateral flow assay kits is expected to create significant growth during the forecast period. Additionally, growing geriatric populations are susceptible to different types of chronic diseases, which enhances the demand for home-based testing methods. This, in turn, is expected to boost market growth during the forecast period. Besides, growing public awareness about the new testing assay is also propelling market growth through 2028. , during the 2019-2020 flu season, there were 36 million cases of influenza in the United States. The number of influenza deaths during the 2019-2020 flu season was 20,342. The vast majority of deaths attributed to influenza during the 2019-2020 flu season occurred among those aged 65 years and older.Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Growing prevalence of infectious diseases
Chronic illnesses such as cystic fibrosis, cardiovascular diseases, hepatitis, and cancer are rapidly increasing due to physiological changes, metabolic problems, and low immune systems, and so the aging population is prone to these types of chronic diseases, which will enhance the growth of the market during the forecast period. Similarly, changing a healthy lifestyle will enhance disease growth across the region, and this, in turn, will boost the market growth during the forecast period. In September 2020, Qiagen N.V. bought NeuMoDx Molecular, Inc. to expand Qiagen's diagnostics instrument product line and boost its market position in automated molecular testing. This will broaden QIAGEN's offering of automated testing solutions and serve as another catalyst for future growth. Government initiative and awareness about using new assays will boost the market growth during the forecast period. During 2021, a total of 7,860 TB cases were provisionally reported to CDC’s National Tuberculosis Surveillance System (NTSS) by the 50 U.S. states and the District of Columbia (DC). The increasing prevalence of infectious diseases like HIV and malaria due to consuming unhealthy food is expected to create lucrative growth during the forecast period. Due to the increasing prevalence of chronic diseases, demand leading a healthy lifestyle increased, which is further expected to drive the growth of the market over the years. Around 46% of all diseases worldwide and 60% of the 56.5 million deaths in 2001 were due to chronic conditions.Increasing demand for home-based testing method
Rising demand for home-based testing kits for the detection of chronic diseases, pregnancy tests, fertility tests, coagulation tests, urine chemistry, etc., the growing demand for point-of-care testing may further enhance the demand for lateral flow assay, and usage of this device is rapidly increased which may further propel the growth of the market during the forecast period. According to this Statista, 7.92 million women in the U.S. used home pregnancy tests in 2020. Major companies are focusing on developing innovative lateral flow assay-based point-of-care devices for applications such as pregnancy tests by using HCG levels and ovulation, careening for infectious diseases ad drugs, and the measurement of protein markers in the boost is expected to enhance the demand for lateral flow assay market over the years. For instance, in 2019, Abbott Laboratories (US) developed its ARCHITECT stat Troponin I blood test, while Siemens AG developed the CLINITEK Microalbumin 2 strips for clinical diagnostics.Market Segmentation
The global lateral flow assay market can be segmented by product, application, technique, test type, end-user, and by region. Based on the product, the market can be segmented into Kits & Reagents, Lateral Flow Readers, and Others. Based on application, the market can be segmented into Clinical Testing, Cardiac Marker Testing, Pregnancy & Fertility Testing, Veterinary Diagnostics, and Others. Based on technique, the market can be differentiated by Sandwich Assay, Competitive Assay, and Multiplex Detection Assay. Based on test type, the market can be divided into Lateral Flow Immunoassay and Nucleic Acid Lateral Flow Assay. Based on end-user, the market can be differentiated into Hospitals & Clinics, Diagnostic Laboratories, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, the Middle East & Africa, and South America. Among different countries, the United States dominates the global lateral flow assay market on account of the growing prevalence of infectious diseases and the demand for new technology with affordable costs in the country. Reported TB incidence (cases per 100,000 persons) increased by 9.4%, from 2.2 in 2020 to 2.4 in 2021 but was lower than incidence during 2019 (2.7). Increases occurred among both U.S.-born and non-U.S.-born persons.Market Players
Thermo Fisher Scientific, Inc., Abbott Laboratories, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Quidel Corporation, Hologic, Inc., bioMérieux SA, PerkinElmer, Inc., Danaher Corporation, QIAGEN N.V. are some of the leading players operating in the Global Lateral Flow Assay Market.Recent Development
Novacyt, a specialist in clinical diagnostics, is to launch two PathFlow COVID-19 antigen lateral flow tests (LFTs) to strengthen its COVID-19 portfolio and to pursue new market opportunities, especially in point-of-care (POC) settings. In September 2020, F. Hoffmann-La Roche AG (Switzerland) launched a SARS-CoV-2 rapid antigen test kit and a SARS-CoV-2 rapid antibody test kit.Report Scope:
In this report, the global lateral flow assay market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:Lateral Flow Assay Market, By Product:
- Kits & Reagents
- Lateral Flow Readers
- Others
Lateral Flow Assay Market, By Application:
- Clinical Testing
- Cardiac Marker Testing
- Pregnancy & Fertility Testing
- Veterinary Diagnostics
- Others
Lateral Flow Assay Market, By Technique:
- Sandwich Assay
- Competitive Assay
- Multiplex Detection Assay
Lateral Flow Assay Market, By Test Type:
- Lateral Flow Immunoassay
- Nucleic Acid Lateral Flow Assay
Lateral Flow Assay Market, By End User:
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
Lateral Flow Assay Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive landscape
Company Profiles: Detailed analysis of the major companies present in the Global Lateral Flow Assay Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Lateral Flow Assay Market Outlook
6. North America Lateral Flow Assay Market Outlook
7. Europe Lateral Flow Assay Market Outlook
8. Asia-Pacific Lateral Flow Assay Market Outlook
9. South America Lateral Flow Assay Market Outlook
10. Middle East and Africa Lateral Flow Assay Market Outlook
11. Market Dynamics
12. Market Trends & Developments
14. Porter’s Five Forces Analysis
15. Competitive Landscape
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Bio-Rad Laboratories, Inc.
- Quidel Corporation
- Hologic, Inc.
- bioMérieux SA
- PerkinElmer, Inc.
- Danaher Corporation
- QIAGEN N.V.